240 related articles for article (PubMed ID: 22529279)
41. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.
Pollok J; van Agteren JE; Carson-Chahhoud KV
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012346. PubMed ID: 30566235
[TBL] [Abstract][Full Text] [Related]
42. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.
Siafis S; Çıray O; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S
Mol Autism; 2020 Aug; 11(1):66. PubMed ID: 32847616
[TBL] [Abstract][Full Text] [Related]
43. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Legg LA; Tilney R; Hsieh CF; Wu S; Lundström E; Rudberg AS; Kutlubaev MA; Dennis M; Soleimani B; Barugh A; Hackett ML; Hankey GJ; Mead GE
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31769878
[TBL] [Abstract][Full Text] [Related]
44. Antidepressants for the treatment of depression in people with cancer.
Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011006. PubMed ID: 26029972
[TBL] [Abstract][Full Text] [Related]
45. The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.
Aye SZ; Ni H; Sein HH; Mon ST; Zheng Q; Wong YKY
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013457. PubMed ID: 33583058
[TBL] [Abstract][Full Text] [Related]
46. Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder.
Thom RP; Pereira JA; Sipsock D; McDougle CJ
Curr Psychiatry Rep; 2021 Oct; 23(12):79. PubMed ID: 34643815
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias.
Cuijpers P; Smit F; Bohlmeijer E; Hollon SD; Andersson G
Br J Psychiatry; 2010 Mar; 196(3):173-8. PubMed ID: 20194536
[TBL] [Abstract][Full Text] [Related]
48. Drug fails to subdue repetitive behavior in children with autism spectrum disorders.
Harv Ment Health Lett; 2009 Oct; 26(4):7. PubMed ID: 19904836
[No Abstract] [Full Text] [Related]
49. Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):481-5. PubMed ID: 25369243
[TBL] [Abstract][Full Text] [Related]
50. Evidence-based behavioral interventions for repetitive behaviors in autism.
Boyd BA; McDonough SG; Bodfish JW
J Autism Dev Disord; 2012 Jun; 42(6):1236-48. PubMed ID: 21584849
[TBL] [Abstract][Full Text] [Related]
51. Psychopharmacology of autistic spectrum disorders in children and adolescents.
Nazeer A
Pediatr Clin North Am; 2011 Feb; 58(1):85-97, x. PubMed ID: 21281850
[TBL] [Abstract][Full Text] [Related]
52. Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished - a cross-sectional analysis.
Mechler K; Hoffmann GF; Dittmann RW; Ries M
Int J Methods Psychiatr Res; 2017 Dec; 26(4):. PubMed ID: 27862603
[TBL] [Abstract][Full Text] [Related]
53. Subcategories of restricted and repetitive behaviors in children with autism spectrum disorders.
Bishop SL; Hus V; Duncan A; Huerta M; Gotham K; Pickles A; Kreiger A; Buja A; Lund S; Lord C
J Autism Dev Disord; 2013 Jun; 43(6):1287-97. PubMed ID: 23065116
[TBL] [Abstract][Full Text] [Related]
54. Repetitive transcranial magnetic stimulation (r-TMS) and selective serotonin reuptake inhibitor-resistance in obsessive-compulsive disorder: A meta-analysis and clinical implications.
Pellegrini L; Garg K; Enara A; Gottlieb DS; Wellsted D; Albert U; Laws KR; Fineberg NA
Compr Psychiatry; 2022 Oct; 118():152339. PubMed ID: 35917621
[TBL] [Abstract][Full Text] [Related]
55. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications.
Moreno SG; Sutton AJ; Turner EH; Abrams KR; Cooper NJ; Palmer TM; Ades AE
BMJ; 2009 Aug; 339():b2981. PubMed ID: 19666685
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic effects of antidepressants for global improvement and subdomain symptoms of autism spectrum disorder: a systematic review and meta-analysis.
Liang SC; Sun CK; Fan HY; Chung W; Tzang RF; Hung KC; Chiu HJ; Cheng YS; Yeh PY
J Psychiatry Neurosci; 2022; 47(4):E299-E310. PubMed ID: 35948343
[TBL] [Abstract][Full Text] [Related]
57. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G; Naja WJ; Pelissolo A
Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
[TBL] [Abstract][Full Text] [Related]
58. The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Evans VC; Alamian G; McLeod J; Woo C; Yatham LN; Lam RW
CNS Drugs; 2016 May; 30(5):405-17. PubMed ID: 27113464
[TBL] [Abstract][Full Text] [Related]
59. Acupuncture for autism spectrum disorders (ASD).
Cheuk DK; Wong V; Chen WX
Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD007849. PubMed ID: 21901712
[TBL] [Abstract][Full Text] [Related]
60. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
